ArticleMikrochimica acta2026
Spatially designed electrochemical sensor for simultaneous detection of total and phosphorylated neurofilament light chain in neurodegeneration.
Article in Mikrochimica acta, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Ultrasensitive Detection of Neurofilament Light in Plasma Using F(Ab')Small (Weinheim an der Bergstrasse, Germany) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Phosphorylation plays a pivotal role in neurodegenerative diseases, and the ratio of phosphorylated neurofilament light chains (pNfL) to total neurofilament light chains (tNfL) (pNfL/tNfL) has emerged as a promising biomarker. Detecting serum pNfL/tNfL remains challenging due to the extremely low abundance of pNfL. Effective detection requires spatial differentiation between protein capture sites, recognition sites, and post‑translational modification sites, together with precise spatial compatibility among multiple signal amplification sources to simultaneously identify proteins and their phosphorylation states. In this study, we systematically analyzed the structure of pNfL to identify optimal capture and recognition sites with distinct spatial localization. Systematic evaluation demonstrated that matching the size of signal amplification particles to the target protein significantly enhances sensor performance. By optimizing particle size, signals of pNfL and tNfL were amplified using 2 nm carbon dots loaded with Cu2+/Ti4+ and an antibody–horseradish peroxidase complex, respectively. Coupled with an interface–solution dual‑pathway amplification strategy, this approach enabled convenient one‑step dual-signal electrochemical quantification of pNfL/tNfL. The developed sensor exhibited excellent sensitivity, selectivity, and reproducibility, with dynamic ranges of 0.2–20 pg·mL− 1 for both tNfL and pNfL. Preliminary serum analysis suggested that the pNfL/tNfL ratio provide improved discriminatory capability between neurodegenerative conditions, non-neurodegenerative brain injury, and healthy controls. Notably, the pNfL/tNfL ratio showed improved specificity compared to individual tNfL or pNfL measurements in this exploratory cohort. This work introduces a novel spatial design strategy that integrates particle size optimization with dual-pathway amplification, representing the first one-step dual-signal electrochemical platform capable of simultaneously quantifying total and phosphorylated neurofilament light chains in serum.
Indexed as
Identifiers
41501225What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.